Organization | Ludwig Institute for Cancer Research

Ludwig Institute for Cancer Research Report issue

Academic/Hospital Phase 1 Phase 2

Founded: Zurich Switzerland (1971)

Organization Overview

First Clinical Trial

1999

NCT00112216

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Ludwig Institute for Cancer Research

Active Ingredients

Drugs in Phase 2 Trials (35)

111in-dota-cg250 (1 trial)

177lu-dota-cg250 (1 trial)

8 hla-a2 restricted peptides (1 trial)

agatolimod (4 trials)

anti-ox40 (1 trial)

bevacizumab (avastin) (1 trial)

bi 1361849 (1 trial)

busulfan (Myleran) (1 trial)

capecitabine (xeloda) (2 trials)

cyclophosphamide (cytoxan) (2 trials)

doxorubicin (Doxil) (2 trials)

durvalumab (imfinzi) (8 trials)

fludarabine (fludara) (1 trial)

fowlpox-ny-eso-1 vaccine (1 trial)

icosmatrix (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

ipilimumab (yervoy) (5 trials)

kw2871 (1 trial)

mage-3.a1 peptide (1 trial)

mc2 tcr T cells (1 trial)

melphalan (alkeran) (1 trial)

montanide isa51 (6 trials)

montanide isa 720 (4 trials)

nivolumab (opdivo) (2 trials)

ny-eso-1 and melan-a/mart-1 peptides (1 trial)

ny-eso-1 iscomatrix (2 trials)

ny-eso-1 protein (1 trial)

oncos-102 (1 trial)

oxaliplatin (eloxatin) (1 trial)

pegylated arginine deiminase (2 trials)

poly-iclc (4 trials)

recombinant vaccinia-ny-eso-1 vaccine (1 trial)

tremelimumab (Imjudo) (4 trials)

x-396 (1 trial)

Drugs in Phase 1 Trials (38)

111in cmd-193 (1 trial)

111in-cs-1008 (1 trial)

111-indium-ch806 (1 trial)

131i-hua33 (1 trial)

89zr-ds-8895a (1 trial)

alvac ny eso-1 vaccine (1 trial)

bacille calmette-guerin (3 trials)

ch806 (1 trial)

chp-her2, chp-ny-eso-1 (1 trial)

cpg-oligonucleotide (1 trial)

diphenhydramine (benadryl) (1 trial)

dropropizine (1 trial)

ds-8895a (1 trial)

fentanyl (Innovar) (1 trial)

fluma peptide (1 trial)

girentuximab (2 trials)

hua33 (1 trial)

imiquimod (aldara) (1 trial)

levobupivacaine (chirocaine) (1 trial)

mage10 peptide (1 trial)

mage-a10 peptide (1 trial)

mage-a3 asci (1 trial)

masitinib (1 trial)

melan-a analog peptide (3 trials)

mixed bacterial vaccine (1 trial)

ny-eso-1 olp4 (2 trials)

ny-eso-1 peptides (9 trials)

pseudoephedrine (Benylin) (1 trial)

recmage-a3 (1 trial)

romidepsin (istodax) (1 trial)

sargramostim (leukine) (2 trials)

sb-as2 (1 trial)

tigatuzumab (1 trial)

tumor necrosis factor (1 trial)

tyrosinase ymd peptide (1 trial)

y90 conjugated chimeric g250 (1 trial)

y90 monoclonal antibody hu3s193 (1 trial)

Drugs in Other Trials (3)

glucose (1 trial)

sunitinib (sutent) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Appendiceal Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 1)

Colorectal Neoplasms (Phase 1)

Fallopian Tube Neoplasms (Phase 2)

Gastrointestinal Stromal Tumors (Phase 1)

Glioblastoma (Phase 2)

Kidney Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Ovarian Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Recurrence (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Synovial (Phase 2)

Skin Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 1)

Testicular Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 59
# of Trial APIs: 76